FDA Brief

Warning letters Food

FDA warning letter to

Rena's Organic

High riskIssued Feb 11, 2022Posted May 3, 2022Office of Human and Animal Food Operations East Division IV

U.S. Food and Drug Administration (FDA) warned Rena's Organic over unapproved CBD drug claims for tinctures, creams, foods, and pet product.

What happened

FDA reviewed the company's website in February 2022 and its Facebook and Instagram pages, which direct consumers to the site to buy CBD products. FDA found claims that the CBD tinctures, creams, cider, and food treat cancer, opioid addiction, ADHD, insomnia, pain, and other conditions, plus a CBD pet product. FDA said these are unapproved new human and animal drugs, misbranded drugs (drugs with unlawful labeling), and foods with added CBD.

What FDA found

  1. CBD tinctures, creams, cider, and food are promoted as drugs for diseases but are not FDA-approved.

    FD&C Act §§505(a), 301(d); 21 U.S.C. 355(a), 331(d)
  2. These CBD products lack adequate directions for use and are therefore misbranded.

    FD&C Act §502(f)(1); 21 U.S.C. 352(f)(1)
  3. The Pain Relief Creams are unapproved external analgesic drugs, and CBD is not a permitted active ingredient.

    FD&C Act §§505(a), 301(d), 505G; 21 U.S.C. 355(a), 331(d), 355h
  4. The Pain Relief Creams are misbranded because labeling features CBD as an inactive ingredient while implying it has active value.

    FD&C Act §502(a); 21 CFR 201.10(c)(4)
  5. CBD added to conventional foods such as CBD Super Cider and CBD Super Food is prohibited and makes the food adulterated.

    FD&C Act §§301(ll), 409(a), 402(a)(2)(C)(i); 21 U.S.C. 331(ll), 348(a), 342(a)(2)(C)(i)
  6. The pet CBD product is an unapproved new animal drug and is unsafe and adulterated.

    FD&C Act §§512(a), 501(a)(5); 21 U.S.C. 360b(a), 351(a)(5)

What FDA wants

FDA tells the company to correct the violations and warns that failure to do so may lead to legal action. The provided letter excerpt does not state a response deadline.

Who should pay attention

  • CBD brands making disease treatment claims
  • retailers and marketplaces selling CBD tinctures, creams, or foods
  • pet supplement sellers and contract manufacturers of CBD products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk